TJ Bilodeau’s Post

Our report series Measuring the return from pharmaceutical innovation has provided insights into the productivity of biopharma R&D since 2010. We have expanded our analysis over time and our data set now covers the top 20 companies by 2020 R&D spend. The past 14 years have demonstrated that transformational change in R&D productivity is required to reverse the declining trends in returns across the biopharma industry and the ongoing challenge of continuing to deliver innovation to patients. Our latest analysis shows that this conclusion is more relevant than ever, given that companies are facing a more challenging regulatory landscape, growing cost pressures, declining peak sales and difficulties in replenishing their pipelines, with the result that projected R&D returns continue to remain well below the cost of capital.

🚀 Pharmaceutical Manufacturers: Partner with COEUS for Your Market Success 💊 Bringing innovative drugs and therapies to market is no small feat. That’s where COEUS, a pharmaceutical and emerging biotech consulting company that's successfully launched more than 130 drugs, comes in to help you navigate this complex journey with ease. From pre-launch to post-launch, COEUS offers a comprehensive suite of services designed to drive your success. When to Partner with COEUS: Early development: Align market access strategies to streamline payer approval processes. Post-launch: Optimize reimbursement pathways and support long-term product adoption with real-world evidence and payer strategies. Anytime: Enhance communication strategies that resonate with healthcare stakeholders, ensuring that the value of your drug or therapy is recognized and rewarded. Transform your market strategy with COEUS—because success in pharmaceuticals isn’t just about innovation, it’s about the strategy that powers it. For an overview of COEUS’ services, download our company overview: https://conta.cc/3YhT6e2 #PharmaceuticalConsulting #MarketAccess #HEOR #PayerStrategy #RealWorldEvidence #PatientAccess #DrugLaunch #TherapySuccess #COEUSConsulting

Our annual series "Measuring the return from pharmaceutical innovation" analyses the projected IRR that biopharma companies can expect to earn from their late-stage pipelines. The past 14 years have demonstrated that transformational change in R&D productivity is required to reverse the declining trends in returns across the biopharma industry and the ongoing challenge of continuing to deliver innovation to patients. Our latest analysis shows that this conclusion is more relevant than ever, given that companies are facing a more challenging regulatory landscape, growing cost pressures, declining peak sales and difficulties in replenishing their pipelines, with the result that projected R&D returns continue to remain well below the cost of capital.

New product launches are crucial for big pharma’s revenue growth, but about half of them have underperformed in the last 15 years. Despite larger companies typically achieving higher peak revenues, launch successes vary significantly. My colleagues Pierre Jacquet, M.D., Ph.D., Peter Rosenorn, TJ Bilodeau and Kim Quach conducted an analysis of the top 10 biopharmaceutical companies’ launch performances, which accounted for over $230 billion in U.S. net medicine spending in 2021, that provides vital insights for more successful product launches and optimal partner selection for biotechs. Find out more in their latest Executive Insights publication: https://lnkd.in/dZhbuqJq #pharma #pharmaceutical #pharmaceuticals #lifesciences #pharmaceuticalindustry #LEK

Pharmaceutical Success & Its Ripple Effect on Hospitality 🌟 The synergy between pharmaceuticals and hospitality is a powerful reminder of how interconnected industries can drive mutual success. As the pharmaceutical sector thrives, so does the demand for quality hospitality services. Exciting times ahead for both industries! #PharmaceuticalIndustry #HospitalitySector #BusinessTravel #MedicalTourism #IndustryGrowth https://lnkd.in/eB-KUVGk

💊As healthcare budgets continue to tighten, the pharmaceutical industry is becoming increasingly crowded with innovative, expensive medicines. It is more and more challenging for pharma companies to demonstrate the value of their products, negotiate a price that rewards innovation and respond to payers' evolving value assessment approaches and pricing policies. Our white paper explores how pharma companies can overcome these challenges to ensure patients get timely access to innovative medicines at a fair price. Download your copy here: ➡️https://lnkd.in/eSXQzC8e #Pharma #Pharmaceuticals #PharmaceuticalStrategy #Biopharma #Strategy #Consulting #OperationalExcellence #ValueandAccess #MarketAccess #Innovation #Pricing #ValueMeasures

Collaboration is key in the pharmaceutical industry, and CDMOs provide a collaborative framework for companies to leverage external expertise. This approach fosters innovation, knowledge sharing, and ultimately, success in bringing breakthrough therapies to patients. A strategic partnership will make a global impact in the pharmaceutical realm! #partnership #collaboration #knowledgesharing #cdmo #pharmaceuticalmanufacturing

Tune in to hear PwC specialists discuss strategies to reinvent the pharma business model and drive growth in the pharmaceutical industry.

Tune in to hear PwC specialists discuss strategies to reinvent the pharma business model and drive growth in the pharmaceutical industry.

Tune in to hear PwC specialists discuss strategies to reinvent the pharma business model and drive growth in the pharmaceutical industry.